Ascendis Pharma

ASND

Equity

ISIN US04351P1012 / Valor 26912602

NASDAQ (2025-03-14)

USD 152.98+0.44%

Ascendis Pharma
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Ascendis Pharma, founded in 2007, is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing innovative therapies for rare endocrine diseases. The company is publicly traded on the Nasdaq since 2015 and has a global presence with employees dedicated to improving patients' lives. In 2018, Ascendis Pharma formed VISEN Pharmaceuticals to focus on endocrinology and granted exclusive rights to develop and commercialize its rare disease therapies in Greater China. Key products include TransCon hGH, TransCon PTH, and TransCon CNP.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

In the third quarter of 2024, Ascendis Pharma reported a revenue of EUR 57,833,000, marking an increase from EUR 48,034,000 in the same period of 2023. This growth reflects the company's expanding market presence and successful product sales.

Operating Loss

Ascendis Pharma experienced an operating loss of EUR 96,743,000 in Q3 2024, which is an improvement compared to the loss of EUR 134,407,000 in Q3 2023. The reduction in operating loss indicates better cost management and operational efficiency.

Net Loss

The net loss for Ascendis Pharma in the third quarter of 2024 was EUR 99,198,000, compared to a net loss of EUR 162,223,000 in the same quarter of the previous year. This decrease in net loss suggests progress towards financial stability.

Earnings Per Share

For Q3 2024, Ascendis Pharma reported a basic and diluted loss per share of EUR 1.72, an improvement from the loss of EUR 2.88 per share in Q3 2023. This improvement reflects the company's efforts to enhance shareholder value despite ongoing challenges.

Financial Outlook

Ascendis Pharma's financial outlook remains cautiously optimistic as the company continues to focus on strategic initiatives to drive revenue growth and reduce losses. The positive trends in revenue and reduced losses in Q3 2024 provide a foundation for future financial performance improvements.

Summarized from source with an LLMView Source

Key figures

2.06%1Y

49.0%3Y

39.9%5Y

Performance

40.7%1Y

52.7%3Y

49.1%5Y

Volatility